MedTrace Logo

NOX-100 for Preventing Hypotension During Hemodialysis

NCT01672008 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2015-12-31

No results posted yet for this study

Summary

This study is designed to evaluate the safety, tolerability and efficacy profile of NOX-100 to reduce intradialytic hypotension (IDH) in patients undergoing chronic hemodialysis (HD).

Conditions

Interventions

DRUG

NOX-100

Sponsors & Collaborators

  • Orient Europharma Co., Ltd.

    collaborator INDUSTRY

  • Medinox, Inc.

    lead INDUSTRY

Principal Investigators

  • Monte Lai, Ph.D. · Medinox, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01672008 on ClinicalTrials.gov